Lantheus (NASDAQ:LNTH) Stock Price Expected to Rise, Truist Financial Analyst Says

Lantheus (NASDAQ:LNTH) had its target price upped by stock analysts at Truist Financial from $89.00 to $98.00 in a research report issued on Wednesday, MarketBeat reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target would suggest a potential upside of 16.78% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 28th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Mizuho lifted their price target on shares of Lantheus from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $88.86.

Lantheus Trading Down 0.0%

Shares of LNTH opened at $83.92 on Wednesday. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm’s 50-day moving average is $75.99 and its two-hundred day moving average is $65.88. Lantheus has a twelve month low of $47.25 and a twelve month high of $108.91. The firm has a market capitalization of $5.46 billion, a P/E ratio of 24.90 and a beta of -0.12.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same period last year, the firm earned $1.59 EPS. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its stake in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Blue Trust Inc. grew its stake in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares during the last quarter. Vident Advisory LLC grew its stake in Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after acquiring an additional 230 shares during the last quarter. United Community Bank grew its stake in Lantheus by 15.6% in the 3rd quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 245 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.